Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acquired resistance to immunotherapy and future challenges.

Literature DB >> 26822578

Acquired resistance to immunotherapy and future challenges.

Nicholas P Restifo¹, Mark J Smyth², Alexandra Snyder³.

Abstract

Advances in immunotherapy have resulted in remarkable clinical responses in some patients. However, one of the biggest challenges in cancer therapeutics is the development of resistant disease and disease progression on or after therapy. Given that many patients have now received various types of immunotherapy, we asked three scientists to give their views on the current evidence for whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 26822578 PMCID： PMC6330026 DOI： 10.1038/nrc.2016.2

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

47 in total

Review 1. Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors: Antoni Ribas
Journal: Cancer Discov Date: 2015-08-13 Impact factor: 39.397

Review 2. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors: Hung T Khong; Nicholas P Restifo
Journal: Nat Immunol Date: 2002-11 Impact factor: 25.606

3. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors: Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal: Nature Date: 2015-05-11 Impact factor: 49.962

4. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

6. Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors: Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal: Nat Med Date: 2016-01 Impact factor: 53.440

7. Adaptive immunity maintains occult cancer in an equilibrium state.

Authors: Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal: Nature Date: 2007-11-18 Impact factor: 49.962

8. Expression of tumour-specific antigens underlies cancer immunoediting.

Authors: Michel DuPage; Claire Mazumdar; Leah M Schmidt; Ann F Cheung; Tyler Jacks
Journal: Nature Date: 2012-02-08 Impact factor: 49.962

9. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma.

Authors: M J Smyth; K Y Thia; S E Street; D MacGregor; D I Godfrey; J A Trapani
Journal: J Exp Med Date: 2000-09-04 Impact factor: 14.307

10. Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

Authors: Timothy O'Sullivan; Robert Saddawi-Konefka; William Vermi; Catherine M Koebel; Cora Arthur; J Michael White; Ravi Uppaluri; Daniel M Andrews; Shin Foong Ngiow; Michele W L Teng; Mark J Smyth; Robert D Schreiber; Jack D Bui
Journal: J Exp Med Date: 2012-08-27 Impact factor: 14.307

159 in total

1. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Authors: Hojabr Kakavand; Louise A Jackett; Alexander M Menzies; Tuba N Gide; Matteo S Carlino; Robyn P M Saw; John F Thompson; James S Wilmott; Georgina V Long; Richard A Scolyer
Journal: Mod Pathol Date: 2017-08-04 Impact factor: 7.842

Acquired resistance to immunotherapy and future challenges.

Review 1. Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Review 2. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

3. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

4. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

6. Prospects for gene-engineered T cell immunotherapy for solid cancers.

7. Adaptive immunity maintains occult cancer in an equilibrium state.

8. Expression of tumour-specific antigens underlies cancer immunoediting.

9. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma.

10. Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

1. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Review 2. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Review 3. DNA Damage and Repair Biomarkers of Immunotherapy Response.

Review 4. Resistance to immunotherapy: clouds in a bright sky.

Review 5. Delivery technologies for cancer immunotherapy.

Review 6. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Review 7. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Review 8. Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity.

Review 9. Regulatory circuits of T cell function in cancer.

10. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.